HopeStage
Back to all studies
CompletedNCT03201757

Long-Term ALKS 3831 Safety in Schizophrenia or Bipolarity

About this titleRead the official source — NCT03201757
Medication studyAges 16–70Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 16 years to 70 years.

Listed locations
Little Rock and 84 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 15, 2017
Recruitment status
Completed
Enrollment listed in the registry
523
Sponsor
Alkermes, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, United Kingdom, Austria, ...
Age range
From 16 Years to 70 Years
Official registry ID
NCT03201757
Official title
Show the full official title

A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock, United States · Rogers, United States · Anaheim, United States

77 more locations
  • Cerritos, United States
  • Culver City, United States
  • Garden Grove, United States
  • Glendale, United States
  • Long Beach, United States
  • Oakland, United States
  • Oceanside, United States
  • Orange, United States
  • Palo Alto, United States
  • Pico Rivera, United States
  • Redlands, United States
  • San Diego, United States
  • Temecula, United States
  • Torrance, United States
  • Lauderhill, United States
  • North Miami, United States
  • Atlanta, United States
  • Augusta, United States
  • Decatur, United States
  • Chicago, United States
  • Winfield, United States
  • Grand Rapids, United States
  • Flowood, United States
  • Kansas City, United States
  • St Louis, United States
  • Las Vegas, United States
  • Berlin, United States
  • Marlton, United States
  • Brooklyn, United States
  • Rochester, United States
  • Canton, United States
  • Cincinnati, United States
  • Dayton, United States
  • Eugene, United States
  • Austin, United States
  • DeSoto, United States
  • Fort Worth, United States
  • Houston, United States
  • Richardson, United States
  • Bellevue, United States
  • Vienna, Austria
  • Burgas, Bulgaria
  • Lovech, Bulgaria
  • Novi Iskar, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Tserova Koria, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Galway, Ireland
  • Jerusalem, Israel
  • Ramat Gan, Israel
  • Brescia, Italy
  • Naples, Italy
  • Poznan, Poland
  • San Juan, Puerto Rico
  • Arkhangelsk, Russia
  • Moscow, Russia
  • Roshchino, Russia
  • Rostov-on-Don, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Saratov, Russia
  • Tonnel'nyy, Russia
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Novi Kneževac, Serbia
  • Busan, South Korea
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Poltava, Ukraine
  • Smila, Ukraine
  • Vinnytsia, Ukraine
  • Headington, United Kingdom
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including ALKS 3831.

Who was this study for?

Listed age limits: 16 years to 70 years.

Want to explore more studies?

Explore studies